Multidisciplinary treatment approach on medication related osteonecrosis of jaw in oncologic patients treated with intravenous bisphosphonates

Creative Commons License

Karaca Ç., Köseoğlu O. T. , Er N., Kösemehmetoğlu K., Özer T., Topaloğlu G., ...More

22nd International Conference on Oral & Maxillofacial Surgery, Melbourne, Australia, 27 - 30 October 2015, vol.44, pp.238

  • Publication Type: Conference Paper / Summary Text
  • Volume: 44
  • Doi Number: 10.1016/j.ijom.2015.08.163
  • City: Melbourne
  • Country: Australia
  • Page Numbers: pp.238


Bisphosphonates are a group of drugs that have been widely used for their antiresoptive, antiangiogenic and antitumoral effects in medical practice.

Bisphosphonate-related osteonecrosis of jaw (BRONJ) was firstly reported in 2003and since then several studies about the definition, the mechanism and the treatment consept of BRONJ have been presented by both American Association of Oral and Maxillofacial Surgeons (AAOMS) and the other task forces. Recently AAOMS have recommended to change the nomenculature BRONJ because of the growing number of osteonecrosis cases associated with other antiresorptive and antiangiogenic therapies. Therefore the term medication-related osteonecrosis of jaw (MRONJ) has been used in the current literature.

The purpose of this study is to explain the treatment protocol on MRONJ patients in Hacettepe University, Faculty of Den- tistry, and Turkey. In this case series, 9 oncologic patients with stage-2 MRONJ treated by multidisciplinary approach including Department of Oral and Maxillofacial Surgery, Internal Medicine, Medical Pathology, Prosthodontics will be presented. It will be discussed the medical regimens, surgical interventions and prosthodontic rehabilitation in MRONJ patients compared with the current literature.